drugset
drugset / Trial / NCT02748707

Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study

NCT02748707 ↗

Phase 2 Unknown 64 enrolled Tata Memorial Hospital
RandomizedFactorialOpen-labelTreatment

Summary

This is a phase II randomized clinical trial to study the effect of COX-2 inhibitor Celecoxib and EGFR tyrosine kinase inhibitor Erlotinib alone or in combination on molecular markers of apoptosis and angiogenesis.

Timeline

Start
2015-08-18
Primary completion
2018-02-12
Completion
2023-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral
Subject Erlotinib Small molecule 150 mg Oral

Indications

squamous cell carcinoma of buccal mucosa tongue cancer